Agilex Biolabs Toxicology Tapped for SARS-CoV-2 Vaccine Research Agilex Biolabs said biotechs with first-in-human studies can leverage significant quality, speed and cost advantages working with their company TetraQ toxicology for pre-clinical research in Australia.
BriefingWire.com, 5/17/2021 - ADELAIDE, AUS, May 17, 2021 - (ACN Newswire) - Agilex Biolabs, Australia s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, said biotechs with first-in-human studies can leverage significant quality, speed and cost advantages working with their company TetraQ toxicology for pre-clinical research in Australia.
TetraQ is a NATA-accredited, GLP-recognised rodent toxicology facility.
The TetraQ toxicology team, whose recent COVID-19 vaccine work is featured in PubMed, is one of the most experienced in the region with more than 15 years of success with biotechs and university researchers. In a